Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study

BACKGROUND: In ASPIRE, carfilzomib, lenalidomide, and dexamethasone (KRd) significantly improved progression-free survival (PFS) and response rates versus lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma. Per protocol, patients received KRd for a maximum of 18 cycles fo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Hematol Oncol
Autores principales: Dimopoulos, Meletios, Wang, Michael, Maisnar, Vladimir, Minarik, Jiri, Bensinger, William, Mateos, Maria-Victoria, Obreja, Mihaela, Blaedel, Julie, Moreau, Philippe
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5883881/
https://ncbi.nlm.nih.gov/pubmed/29615082
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-018-0583-7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares